Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies

Atamyıldız Uçar S., SÖZERİ B.

Expert Opinion on Biological Therapy, cilt.25, sa.8, ss.835-846, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 25 Sayı: 8
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1080/14712598.2025.2536351
  • Dergi Adı: Expert Opinion on Biological Therapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.835-846
  • Anahtar Kelimeler: Anti-tumor necrosis factor alpha inhibitors, anti interleukin-1 therapy, anti interleukin-6 therapy, biologic DMARDs, biological therapy, juvenile idiopathic arthritis, real-world study
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Introduction: This review aims to summarize real-world evidence on the use of biologic therapies in juvenile idiopathic arthritis (JIA), including systemic and non-systemic subtypes, and to explore treatment strategies. Areas covered: The evolving therapeutic landscape of JIA, emphasizing the differential efficacy and safety profiles of biologic agents such as IL-1 and IL-6 inhibitors, TNF inhibitors, secukinumab and abatacept across JIA subtypes. Special attention is given to real-world registry data, observational studies, and cohort analyses evaluating treatment responses, disease remission rates, flare risk after biologic discontinuation, and the effectiveness of biosimilars. Evidence regarding biologic switching strategies and the challenges of treating difficult-to-manage subtypes such as systemic JIA and enthesitis-related arthritis are also addressed. Expert opinion: Earlier use of biologic agents may become more widely accepted, particularly in high-risk JIA subtypes. This shift has the potential to promote earlier remission, reduce long-term joint damage and corticosteroid dependency, and minimize hospitalization and complications. However, this approach must be carefully balanced against increased treatment costs and potential long-term dependence on biologics.